2022-05-11T17:39:07-05:00 2021-06-30 ERNST & YOUNG US LLP 4365 EXECUTIVE DR STE 1600 SAN DIEGO CA 92121 990 2020-07-01 510197108 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE % AMARENDRA DUVVUR SANF 8586463100 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 AMARENDRA DUVVUR CFO 8586463100 2022-05-10 true AMARENDRA DUVVUR 999009999 JOCELYNE MILLER P00634378 8585357200 2 2020 2022-09-23 18:48:47Z KRISTIINA VUORI MD PHD 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 279331753 false X WWW.SBPDISCOVERY.ORG X 1976 CA SEE SCHEDULE O 19 17 696 19 1705259 0 100963692 111444313 643286 853344 12481799 8321052 2641626 4108275 116730403 124726984 0 0 0 0 62755446 58840604 0 0 1447258 49892483 50083471 112647929 108924075 4082474 15802909 307274683 337147969 93150241 76437099 214124442 260710870 X SEE SCHEDULE O false false 86337145 0 968358 SEE SCHEDULE O 86337145 true true false true false false false false false true true true false false true true true false false true true false false false false false false false false true true false false false false false true false false false false true false false false false false false false false true 162 0 true 696 true true true false false false false true true false false false false true false X 19 17 false false false false false false false true true false false true true true true true true true true false AL AK AR CA CO CT DC FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X AMARENDRA DUVVUR 8586463100 10901 NORTH TORREY PINES RD LA JOLLA CA 92037 KRISTIINA VUORI MD PHD PRESIDENT 50.0 0.0 X X 2599463 0 53106 C RANDAL MILLS PHD CEO 50.0 0.0 X X 564836 0 100574 GARTH POWIS PHD CENTER DIRECTOR 50.0 0.0 X 464625 0 50891 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 50.0 0.0 X 418564 0 56754 CARL WARE PHD CENTER DIRECTOR, IIDC 50.0 0.0 X 405773 0 55843 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 50.0 0.0 X 388639 0 64168 LOUIS COFFMAN CAO & CFO 50.0 0.0 X 390278 0 55788 ZE'EV RONAI PHD PROGRAM DIRECTOR 50.0 0.0 X 354747 0 68113 ANNA BARKER PHD TRUSTEE 1.0 0.0 X 0 0 0 DAN EPSTEIN TRUSTEE 1.0 0.0 X 0 0 0 DAVID DOWN TRUSTEE 1.0 0.0 X 0 0 0 DAVID SZEKERES TRUSTEE 1.0 0.0 X 0 0 0 DONALD KERNS PHD TRUSTEE 1.0 0.0 X 0 0 0 DOUGLAS OBENSHAIN TRUSTEE 1.0 0.0 X 0 0 0 HENRY NORDOFF TRUSTEE 1.0 0.0 X 0 0 0 JAMES BLAIR PHD CHAIRMAN 1.0 0.0 X X 0 0 0 JAMES JARDON TRUSTEE 1.0 0.0 X 0 0 0 JAMES MYERS TRUSTEE 1.0 0.0 X 0 0 0 KAREN HAYNES PHD TRUSTEE 1.0 0.0 X 0 0 0 KATHERINE CHAPIN TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 KAZUMI SHIOSAKI PHD TRUSTEE 1.0 0.0 X 0 0 0 MATTHEW BROWNE TRUSTEE 1.0 0.0 X 0 0 0 PETER SEIDLER TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 STUART TANZ TRUSTEE 1.0 0.0 X 0 0 0 WILLIAM GERHART VICE CHAIRMAN 1.0 0.0 X X 0 0 0 WILLIAM ROPER TRUSTEE 1.0 0.0 X 0 0 0 KNOX BELL CORPORATE SECRETARY 2.0 0.0 X 0 0 0 5586925 0 505237 117 false true false DPR CONSTRUCTION 1450 VETERANS BLVD REDWOOD CITY CA 94063 CONSTRUCTION SRVICES 666044 WILSON SONSINI GOODRICH PO BOX 742866 LOS ANGELES CA 90074 LEGAL SERVICES 377383 DELOITTE TOUCHE LLP PO BOX 844708 DALLAS TX 75284 AUDIT SERVICES 303117 CARY THOMAS 3581 SEAVIEW WAY CARLSBAD CA 92008 CONSULTING 224733 FITCH CONTRACTING CO 9011 LOS COCHES ROAD LAKESIDE CA 92040 CONSTRUCTION SRVICES 212900 9 63708300 47736013 130000 111444313 SHARED SERVICES REVENUE 541990 853344 853344 853344 2949544 2949544 0 0 2275762 2275762 12240 12240 0 12240 12240 159976277 154604769 5371508 5371508 5371508 0 0 0 0 0 0 0 0 0 RESEARCH 541700 1705259 1705259 EQUIPMENT PROCEEDS 541990 82298 82298 SALE OF REAGENTS 541990 26717 26717 5999 5999 1820273 124726984 968358 1705259 10609054 0 0 0 0 2404489 5793 2398696 0 43157602 33177744 9166487 813371 3021491 2328480 650673 42338 7433905 5316296 2017852 99757 2823117 2103853 669660 49604 1910166 366818 1476011 67337 276367 49245 227122 372221 372221 0 0 654971 654971 1334440 1120804 187550 26086 8483 500 7983 5357657 4928905 406900 21852 1282857 900588 351493 30776 0 9447676 8388325 984079 75272 28152 25981 2164 7 0 178194 133266 36560 8368 1616248 1435875 167443 12930 0 6564887 5832246 680122 52519 199066 199066 RESEARCH SUPPLIES & SVCS 10801063 10801063 SCIENTIFIC COLLABORATIONS 8986112 8986112 RECRUITMENT 805509 274008 421147 110354 TUITION FEES 130180 130180 129222 31063 61472 36687 108924075 86337145 21139672 1447258 8063493 11192166 3899 693 5921294 7396598 416137 1378206 0 0 0 0 189635 1888511 18229 81154 8256177 9873188 162315799 110160512 53392558 52155287 202465901 211700816 28547360 39189707 0 0 0 0 0 2291643 307274683 337147969 12191460 16002021 0 0 30022951 10124024 50935830 47207465 0 0 0 0 0 0 0 0 0 3103589 93150241 76437099 X 184924802 213091315 29199640 47619555 214124442 260710870 307274683 337147969 15802909 30783519 X false true X true true true X 121777889 113630164 108300329 100963692 111444313 556116387 0 0 121777889 113630164 108300329 100963692 111444313 556116387 3345342 552771045 6303751 5346565 5942288 3455907 5237546 26286057 281883 48551 0 0 0 330434 0 582732878 6272988 0.94858 0.92438 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false 0 false 0 false 0 false 0 false 0 false 0 true 2677 2677 false SCHEDULE C, PART II-B, LINE 1I DUES TO A RESEARCH AND BIOMEDICAL ORGANIZATION, A PORTION OF WHICH IS CONSIDERED LOBBYING. 19914852 3687 4470604 852702 23536441 20562387 1005 724999 1373539 19914852 29799743 4000 1337873 1327075 29814541 28681314 502000 1841686 1225257 29799743 25987641 530336 3395420 1232083 28681314 0.00000 0.59710 0.40290 false false 12758161 12758161 89845676 57516459 32329217 37324 37324 59674638 52644053 7030585 52155287 PRIVATE EQUITY LPS 8625682 F TOTAL RETURN HEDGE FUNDS 8173146 F SELECT EQUITY FUNDS 22390879 F 39189707 0 OPERATING LEASE LIABILITIES 2338424 FINANCE LEASE LIABILITIES 765165 3103589 X 155352000 30783519 496921 31280440 124071560 654971 453 655424 124726984 108766000 496921 496921 108269079 654971 25 654996 108924075 SCHEDULE D, PART V, LINE 4 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME. SCHEDULE D, PART X, LINE 2 FIN 48 (ASC 740) FOOTNOTE THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES RECORDED AS OF JUNE 30, 2021 AND 2020. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2021 AND 2020. SCHEDULE D, PART XI, LINE 4B ROUNDING - $453 SCHEDULE D, PART XII, LINE 4B ROUNDING - $25 Europe (Including Iceland and Greenland) 2 Program Services SEE PART V 3182 Central America and the Caribbean Investments 3794249 2 2 3797431 3797431 true false true true true false SCHEDULE F, PART I, LINE 3 PROGRAM SERVICE ACTIVITIES SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE DOES NOT MAINTAIN ONGOING OPERATIONS IN FOREIGN JURISDICTIONS. HOWEVER, THE INSTITUTE'S SCIENTIST DO TRAVEL TO VARIOUS SCIENTIFIC CONFERENCES IN OTHER COUNTRIES TO SHARE THE INSTITUTE'S SCIENTIFIC DISCOVERIES, AS WELL AS, TO LEARN FROM OTHER SCIENTISTS ACROSS THE WORLD. SCHEDULE F, PART I, LINE 3, COLUMN E TYPE OF SERVICE SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. SCHEDULE F, PART I, LINE 3, COLUMN F ACCOUNTING METHOD THE ACCRUAL METHOD OF ACCOUNTING WAS USED TO DETERMINE THE AMOUNTS IN PART I, LINE 3, COLUMN F. X X true true X X X X X X false true false false false false false true false C RANDAL MILLS PHD CEO 564167 0 0 0 669 0 83333 0 17241 0 665410 0 0 0 CARL WARE PHD CENTER DIRECTOR, IIDC 400810 0 0 0 4963 0 28500 0 27343 0 461616 0 0 0 GARTH POWIS PHD CENTER DIRECTOR 409795 50000 4830 28500 22391 515516 0 KRISTIINA VUORI MD PHD PRESIDENT 771320 0 250000 0 1578143 0 28500 0 24606 0 2652569 0 1576129 0 LOUIS COFFMAN CAO & CFO 385315 0 0 0 4963 0 28500 0 27288 0 446066 0 0 0 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 414849 0 0 0 3715 0 28500 0 28254 0 475318 0 0 0 RANDAL KAUFMAN PHD PROGRAM DIRECTOR 383676 0 0 0 4963 0 28500 0 35668 0 452807 0 0 0 ZE'EV RONAI PHD PROGRAM DIRECTOR 350378 0 0 0 4369 0 28500 0 39613 0 422860 0 0 0 FORM 990, SCHEDULE J, PART I, LINE 1A RELOCATION COSTS WERE GROSSED UP FOR OUR CEO, RANDAL MILLS. HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION. FORM 990, SCHEDULE J, PART I, LINE 4B SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN THE PARTICIPANTS OF THE 457(F) DEFERRED COMPENSATION PLAN ARE KRISTIINA VUORI AND C. RANDAL MILLS. VESTING FOR KRISTIINA VUORI OCCURS THE EARLIEST OF 04/01/20 & C. RANDAL MILLS THE EARLIEST OF 07/13/25, OR INVOLUNTARY TERMINATION WITHOUT CAUSE, OR PARTICIPANT'S RESIGNATION FOR GOOD CAUSE, OR THE DATE OF TERMINATION OF THE PLAN. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING OF 100% OF THE VALUE OF THE PARTICIPANT'S INVESTMENT (COMPRISED OF INSTITUTE CONTRIBUTIONS TO THE CORPUS PLUS ANY INVESTMENT GAINS OR LOSSES THEREON). THE AMOUNTS VESTED FOR KRISTIINA VUORI WERE INCLUDED IN CALENDAR YEAR 2020 COMPENSATION AND HAVE BEEN REPORTED ACCORDINGLY ON THE 2020 FORM 990. FORM 990, SCHEDULE J, PART I, LINE 7 NON FIXED PAYMENTS SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED. A COUNTY OF SAN DIEGO 956000934 79742YAQ5 2015-11-12 61963256 SEE PART VI false false false A 0 18288870 61963256 0 0 43385000 289386 0 0 0 0 0 2015 true false true true A false true true true true true 0.01810 0.01810 false false false true A false true false false true false 0 false 0 false true A true SCHEDULE K, PART I, ROW A, COLUMN (F) REFINANCE 2006 AND 2012 BONDS WITH ISSUE DATES OF 02/01/2006 AND 11/15/2012, RESPECTIVELY. SCHEDULE K, PART I, ROW A FOR THE BOND ISSUES LISTED IN PART I, THE ALTERNATIVE PERIOD USED FOR THE REPORTING REQUIREMENTS IN THIS SECTION IS THE TWELVE MONTHS ENDED DECEMBER 31, 2020. C RANDAL MILLS OFFICER QUAL EMP RELOCA LOAN X 1000000 1000000 false true true 1000000 X RESEARCH EQUIPMENT 1 130000 FMV 0 false false false FORM 990, SCHEDULE M, PART I, LINE 25, COLUMN (B) COLUMN B IS REPORTING A COMBINATION OF THE NUMBER OF CONTRIBUTIONS RECEIVED AND THE NUMBER OF ITEMS RECEIVED. FORM 990 , PART I, LINE 1 & PART III, LINE 1 ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. FORM 990, PART III, LINE 4 Sanford Burnham Prebys is an independent nonprofit medical research organization dedicated to uncovering the origins of disease and launching bold new strategies that lay the foundation for cures. Our Institute has deep expertise in fundamental biology and is one of the most comprehensive drug discovery centers in the nonprofit world. Cancer Researchers reveal the internal signals that cells use to maintain energy: Scientists at Sanford Burnham Prebys took a deep dive into a previously overlooked family of proteins and discovered that they are essential to maintaining the energy that cells need to grow and survive. The proteins, known as lipid kinases, produce messengers that help balance cellular metabolism and promote overall health. The findings, published in Developmental Cell, support the pursuit of lipid kinases as promising therapeutic targets for diseases that demand excess energy, such as cancer. Tumor marker may help overcome endocrine treatment-resistant breast cancer: A study led by Svasti Haricharan, Ph.D., identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy. The research, published in Nature Communications, offers a new approach to selecting patients for therapy that targets HER2, a protein that promotes the growth of cancer cells, to avoid disease relapse. Atomic-level insights gained for a key lipid-binding protein implicated in cancer: Francesca Marassi, Ph.D., led research published in Structure that identifies hotspots within a protein called PLEKHA7 as targets for drugs. The drug interacts with a cell's membrane to regulate important intercellular communications and may be key to designing treatments for advanced colon, breast and ovarian cancers. Scientists identify potential drug candidates for deadly pediatric leukemia: Ani Deshpande, Ph.D., led a study published in Blood that found two existing drug candidates-JAK inhibitors and Mepron-that hold potential as treatments for a deadly acute myeloid leukemia subtype that is more common in children. The foundational study is a first step toward finding effective treatments for the hard-to-treat blood cancer. Starving tumors by blocking glutamine uptake: Scientists at Sanford Burnham Prebys identified a drug candidate that blocks the uptake of glutamine, a key food source for many tumors, and slows the growth of melanoma. The drug, SLC1A5, is a small molecule that offers a promising new approach for treating melanoma and other cancers. The research was published in Molecular Cancer Therapeutics. Scientists shrink pancreatic tumors by starving their cellular "neighbors": Cosimo Commisso, Ph.D., led a Cancer Discovery study that demonstrated for the first time that blocking "cell drinking,micropinocytosis, in the thick tissue surrounding a pancreatic tumor slowed tumor growth-providing more evidence that micropinocytosis is a driver of pancreatic cancer growth and an important therapeutic target. New drug combination shows promise as powerful treatment for AML: Peter Adams, Ph.D., led a study published in Nature that identified two drugs that are potent against acute myeloid leukemia when combined, but only weakly effective when used alone. The researchers were able to significantly enhance cancer cell death by jointly administering the drugs that are only partially effective when used as single-agent therapies. Personalized drug screens could guide treatment for children with brain cancer: A collaborative study led by Sanford Burnham Prebys demonstrated that personalized drug screens can be used to identify new therapeutic candidates for medulloblastoma, the most common malignant brain cancer in children. The proof-of-concept study was published in Cancer Research and is the basis for future clinical trials. Scientists kill cancer cells by "shutting the door" to the nucleus: A proof-of-concept study by scientists at Sanford Burnham Prebys found that blocking the construction of nuclear pore complexes shrank aggressive tumors in mice while leaving healthy cells unharmed. The research, published in Cancer Discovery, revealed a new Achilles heel for cancer that may lead to better treatments for deadly tumors such as melanoma, leukemia and colorectal cancer. Scientists discover novel target for pancreatic cancer: Scientists at Sanford Burnham Prebys uncovered a novel drug target, a protein called PPP1R1B, that stops the deadly spread of pancreatic cancer in mice. Published in Gastroenterology, the findings are a first step toward a potential treatment for one of the deadliest cancers known today. A helping hand for cancer immunotherapy: Scientists at Sanford Burnham Prebys demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 inhibitors are currently in clinical trials for cancer, and this research provides a strong rationale for testing the drugs in tumors that are not responsive to checkpoint inhibitors. The research was published in Science Translational Medicine. Degenerative Diseases Researchers dig deeper into how cells transport their waste for energy: Scientists at Sanford Burnham Prebys gained a deeper insight into the intricacies of autophagy, the process in which cells degrade and recycle cellular components. The findings, published in Current Biology, described how the "trash bags" in a cell-called autophagosomes-are tagged to direct their movement to the cellular "recycling plants" where waste is processed. The research opens new paths to understanding the relationship between autophagy and age-related diseases such as cancer and neurological disorders. Fruit flies reveal new insights into space travel's effect on the heart: Karen Ocorr, Ph.D., led a study that demonstrated how fruit flies that spend several weeks on the International Space Station experience profound structural and biochemical changes to their hearts. The research, published in Cell Reports, suggests that astronauts who spend a lengthy amount of time in space could suffer similar effects and may benefit from protective measures to keep their hearts healthy. Drug guides stem cells to desired location, improving their ability to heal: Scientists at Sanford Burnham Prebys created a drug that can lure stem cells to damaged tissue and improve treatment efficacy-a scientific first and a major advance in the field of regenerative medicine. The discovery, published in Proceedings of the National Academy of Sciences (PNAS), could improve current stem cell therapies for degenerative diseases. Scientists uncover a novel approach to treating Duchenne muscular dystrophy: A collaborative study with scientists in Italy found that drugs that target extracellular vesicles within dystrophic muscles can restore their ability to regenerate muscle. The research, published in EMBO Reports, is a promising new approach to treat this incurable muscle-wasting disease. Scientists identify a new drug target for dry age-related macular degeneration: Researchers revealed that a blood protein called vitronectin is a promising drug target for age-related macular degeneration, a leading cause of vision loss in Americans 60 years of age and older. The study, published in Proceedings of the National Academy of Sciences (PNAS), also holds promise for Alzheimer's and heart disease, which are linked to vitronectin. Human Genetics Study supports gene therapy as a promising treatment for soft bone disease: A preclinical study led by scientists at Sanford Burnham Prebys has established that AAV8-TNAP-D10-a gene therapy that replaces a key enzyme found in bone-may be a safe and effective single-dose treatment for hypophosphatasia (HPP). The study, published in the Journal of Bone and Mineral Research and performed in a murine model of the disease, further supports advancing the therapy toward human clinical trials. Immunity and Pathogenesis Leprosy drug holds promise as at-home treatment for COVID-19: A Nature study authored by scientists at Sanford Burnham Prebys found that the leprosy drug clofazimine, which is FDA approved and on the World Health Organization's List of Essential Medicines, exhibits potent antiviral activities against SARS-CoV-2 and prevents the exaggerated inflammatory response associated with severe COVID-19. Scientists identify "immune cop" that detects SARS-CoV-2: Scientists at Sanford Burnham Prebys identified the sensor in human lungs that detects SARS-CoV-2 and signals that it's time to mount an antiviral response. The research, published in Cell Reports, provides insights into the molecular basis of severe disease and may enable new strategies for the treatment and prevention of COVID-19. Nature study identifies 21 existing drugs that could treat COVID-19: A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., a professor at Sanford Burnham Prebys, identified 21 existing drugs that stop the replication of SARS-C FORM 990, PART VI, LINE 11B PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. FORM 990, PART VI, LINE 12C DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES ALL TRUSTEES, PRINCIPAL OFFICERS OR MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS TO ANNUALLY CONFIRM THEIR RECEIPT OF THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY NEW ASSOCIATIONS OR INTERESTS THAT MIGHT POTENTIALLY POSE A CONFLICT. THIS IS A WRITTEN CONFIRMATION THAT SHE OR HE READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, WILL ABIDE BY THE CONFLICT OF INTEREST POLICY AND CERTIFIES DISCLOSURE OF ALL INTERESTS OR RELATIONSHIPS THAT MAY POSE CONFLICTS. IN ADDITION, EACH YEAR NEW TRUSTEES RECEIVE TRAINING REGARDING THE INSTITUTE'S CONFLICT OF INTEREST POLICY, WHICH INCLUDES HOW TO IDENTIFY A CONFLICT OF INTEREST AND HOW TO HANDLE POSSIBLE CONFLICTS OF INTEREST WHEN THEY ARISE. THE COMPLIANCE DEPARTMENT REVIEWS EACH OF THE STATEMENTS AND ASSESSES WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST EXISTS/MAY EXIST AND WHETHER THE INDIVIDUAL SHOULD BE PROHIBITED FROM CONSIDERATION OF RELATED ITEMS. ANY TRUSTEE, PRINCIPAL OFFICER OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WITH A CONFLICT IN A MATTER REQUIRING ACTION BY THE BOARD ARE PROHIBITED FROM PARTICIPATING IN THE BOARD'S DELIBERATIONS AND/OR VOTING ON THE PARTICULAR TRANSACTION OR MATTER IN WHICH HE OR SHE HAS AN INTEREST; AND OTHERWISE REFRAIN FROM EXERTING ANY INFLUENCE TO AFFECT A DECISION. HOWEVER, OTHER MEASURES MAY BE REQUIRED, DEPENDING ON THE NATURE OF AND THE ABILITY TO REASONABLY MANAGE A CONFLICT. FORM 990, PART VI, LINES 15A & 15B PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF THREE INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEO'S COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 10, 2021 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CAO/CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) PROGRAM DIRECTOR/PROFESSOR 7) CANCER CENTER DIRECTOR/PROFESSOR 8) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR FORM 990, PART VI, LINE 19 PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST.